0.00Open1.55Pre Close0 Volume50 Open Interest2.50Strike Price0.00Turnover251.16%IV18.31%PremiumJan 17, 2025Expiry Date1.34Intrinsic Value100Multiplier15DDays to Expiry0.21Extrinsic Value100Contract SizeAmericanOptions Type-0.8994Delta0.3112Gamma0.85Leverage Ratio-0.0031Theta-0.0007Rho-0.76Eff Leverage0.0004Vega
Vor Biopharma Stock Discussion
Was watching this Friday painting a beautiful chart not sure why I didn't enter but I will likely enter Monday.
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
• Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant
• Trem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic window
...
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback From FDA Regarding Registrational Trial Design
No comment yet